TABLE 3.
Expression of CD69 by T-cell subsets
| Phenotype | CD69 expressiona
|
|||||
|---|---|---|---|---|---|---|
| Control subjects
|
MF
|
SS
|
||||
| % | Count/μl | % | Count/μl | % | Count/μl | |
| Total CD3+ | 96.6 (0.8)a | 1,394 (155) | 92.5 (1.7) | 811 (125)b | 82.6 (4.4) | 1,472 (228) |
| CD3+ CD7+c | 96.4 (0.5)d | 1,263 (131) | 93.8 (1.5)d | 727 (112) | 92.3 (2.4) | 344 (87) |
| CD3+ CD7− | 91.4 (2.3) | 123 (24) | 86.1 (2.6) | 82 (17) | 82.9 (4.4) | 1,116 (215)e |
| CD3+ CD4+ | 97.9 (0.4)f | 786 (114) | 88.2 (4.2) | 437 (97) | 86.9 (2.4) | 1,953 (747)g |
| CD3+ CD8+ | 95.6 (1.0)f | 500 (81) | 92.9 (4.2) | 656 (108) | 83.9 (8.1) | 91 (19)g |
Figures represent means ± standard errors of the mean (in parentheses).
Patients with MF had significantly lower numbers of CD69+ T cells than patients with SS and control subjects.
There were significant differences in the numbers of CD69+ CD7+ T cells between study groups.
CD7+ T cells of patients with MF and control subjects had significantly higher percentages of CD69 expression than their autologous CD7− T cells.
Patients with SS had significantly higher numbers of CD69+ CD7− T cells than the other two groups.
Control subjects had significantly higher percentages of CD69+ CD4+ and CD69+ CD8+ T cells than patients with MF and SS.
Patients with SS had significantly higher numbers of CD69+ CD4+ T cells and significantly lower numbers CD69+ CD8+ T cells than patients with MF.